dc.contributor.author | Chiesa, C | |
dc.contributor.author | Sjogreen-Gleisner, K | |
dc.contributor.author | Walrand, S | |
dc.contributor.author | Strigari, L | |
dc.contributor.author | Flux, G | |
dc.contributor.author | Gear, J | |
dc.contributor.author | Stokke, C | |
dc.contributor.author | Gabina, PM | |
dc.contributor.author | Bernhardt, P | |
dc.contributor.author | Konijnenberg, M | |
dc.date.accessioned | 2021-11-30T10:52:45Z | |
dc.date.available | 2021-11-30T10:52:45Z | |
dc.date.issued | 2021-11-12 | |
dc.identifier.citation | EJNMMI physics, 2021, 8 (1), pp. 77 - ? | |
dc.identifier.issn | 2197-7364 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4907 | |
dc.identifier.eissn | 2197-7364 | |
dc.identifier.doi | 10.1186/s40658-021-00394-3 | |
dc.description.abstract | The aim of this standard operational procedure is to standardize the methodology employed for the evaluation of pre- and post-treatment absorbed dose calculations in 90Y microsphere liver radioembolization. Basic assumptions include the permanent trapping of microspheres, the local energy deposition method for voxel dosimetry, and the patient-relative calibration method for activity quantification.The identity of 99mTc albumin macro-aggregates (MAA) and 90Y microsphere biodistribution is also assumed. The large observed discrepancies in some patients between 99mTc-MAA predictions and actual 90Y microsphere distributions for lesions is discussed. Absorbed dose predictions to whole non-tumoural liver are considered more reliable and the basic predictors of toxicity. Treatment planning based on mean absorbed dose delivered to the whole non-tumoural liver is advised, except in super-selective treatments.Given the potential mismatch between MAA simulation and actual therapy, absorbed doses should be calculated both pre- and post-therapy. Distinct evaluation between target tumours and non-tumoural tissue, including lungs in cases of lung shunt, are vital for proper optimization of therapy. Dosimetry should be performed first according to a mean absorbed dose approach, with an optional, but important, voxel level evaluation. Fully corrected 99mTc-MAA Single Photon Emission Computed Tomography (SPECT)/computed tomography (CT) and 90Y TOF PET/CT are regarded as optimal acquisition methodologies, but, for institutes where SPECT/CT is not available, non-attenuation corrected 99mTc-MAA SPECT may be used. This offers better planning quality than non dosimetric methods such as Body Surface Area (BSA) or mono-compartmental dosimetry. Quantitative 90Y bremsstrahlung SPECT can be used if dedicated correction methods are available.The proposed methodology is feasible with standard camera software and a spreadsheet. Available commercial or free software can help facilitate the process and improve calculation time. | |
dc.format | Electronic | |
dc.format.extent | 77 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-06-21 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1186/s40658-021-00394-3 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2021-11-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | EJNMMI physics | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | No embargo | |
dc.contributor.icrauthor | Gear, Jonathan | |